Treating and Assessing Treatment Response: AL Amyloidosis

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Dr Liu is a cardio-oncologist with expertise in echocardiography. Her areas of interest include developing imaging-based strategies to optimize cardiovascular health in patients with cancer.She is also focused on advancing education and training in the field of cardio-oncology.

Dr. Gertz is the Roland Seidler Jr. Professor of the Art of Medicine and Chair Emeritus of the Department of Internal Medicine, at Mayo Clinic in Rochester, Minnesota. He is a Master of the American College of Physicians. Undergraduate degree was awarded with highest distinction from Northwestern University graduating Phi Beta Kappa. Dr. Gertz received his medical degree cum laude from Loyola Medical School in Maywood, Illinois and was elected to Alpha Omega Alpha the medical honor society. He completed a 3-year medical residency at Rush Presbyterian St. Luke’s Hospital in Chicago, Illinois, and was voted Resident of the Year for 2 of those years. He completed training in hematology and oncology at Mayo. He was awarded the Mayo Distinguished Clinician Award for his contributions to patient care. He served 1 year term as president of the Mayo clinic staff officers and counselors. he has served as chair of the division of Hematology and chair of the department of Medicine at Mayo Clinic Rochester. He was the first treasurer of the International Society of Amyloidosis and International Myeloma Society. He has authored over 1000 peer reviewed publications and over 90 book chapters. He serves on the editorial boards of Amyloidosis, Acta Haematologica and Clinical Lymphoma & Myeloma. He is coeditor of Neoplastic Diseases of the Blood. In 2019 The Department of Medicine awarded him its lifetime research achievement award.  In 2021 he was appointed chair of the committee for the Hematology Long Term Knowledge assessment for the American Board of Internal Medicine.